Novo Nordisk AS (STU:NOV) Total Deposits

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:NOV Novo Nordisk AS STU:NOV
77 GF Score
Price €34.77
GF Value €93.02
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS Total Deposits?

Total Deposits only applies to banks.

STU:NOV
77GF Score
Novo Nordisk AS STU:NOV
Total Deposits is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novo Nordisk AS (STU:NOV) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of €34.77 is trading 62.6% below its estimated GF Value™ of €93.02. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for STU:NOV:

  • Total Deposits:
  • GF Value™: €93.02 vs. price of €34.77 (62.6% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the STU:NOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
Novo Nordisk is a global pharmaceutical company and the world leader in diabetes and obesity care, supplying roughly half of the world's insulin. Its GLP-1 medicines, semaglutide marketed as Ozempic and oral Rybelsus for type 2 diabetes and Wegovy for obesity, transformed the treatment of metabolic disease and drove years of exceptional growth, with next-generation candidates including CagriSema in development. The company also holds leading positions in rare endocrine disorders and hemophilia through its rare disease segment. Novo Nordisk invests heavily in manufacturing capacity expansion to meet GLP-1 demand, including major fill-finish acquisitions. Founded in 1923 and headquartered in Bagsvaerd, Denmark, it is controlled by the Novo Nordisk Foundation; sales span roughly 170 countries, with the United States its largest market. Its ADRs trade on the NYSE.
77GF Score

Get the complete analysis for STU:NOV

Total Deposits is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€34.77
Price
€93.02
GF Value